Direct cholinergic agonists have a longer duration of action than ACh.

Direct cholinergic agonists are designed to mimic acetylcholine (ACh) and activate cholinergic receptors in the body. One key aspect of these agonists is their pharmacokinetics, specifically their duration of action. While ACh itself is rapidly broken down by the enzyme acetylcholinesterase in the synaptic cleft, resulting in a very short duration of action, many direct cholinergic agonists are resistant to this degradation.

The longer duration of action of direct cholinergic agonists compared to ACh is due to chemical modifications in their structure that make them less susceptible to enzymatic breakdown. For example, certain agonists, like bethanechol and pilocarpine, are designed to have a prolonged effect, allowing for more sustained receptor activation. This characteristic is particularly beneficial in therapeutic applications where a longer-lasting effect is required, such as in treating urinary retention or glaucoma.

Thus, the assertion that direct cholinergic agonists can have a longer duration of action than ACh is accurate, reflecting the fundamental pharmacological properties of these agents.